Background: Pancreatic cancer represents the fourth cause of cancer-related death worldwide. Knowledge of potentially useful prognotics factors is essential to guide different treatment approaches, particularly in the palliative setting.Methods: We collected data from patients in the period of December 2019 to December 2020. They had received FOLFIRINOX or gemcitabine-abraxane as first-line treatment to compare the frequency of non-tumor-related fractures in each treatment group. A retrospective, single-center statistical analysis was carried out where the outcome variable was the appearance of an osteoporotic fracture, analyzed by means of a time-to-event analysis, following the Kaplan-Meyer method. A multivariate analysis was performed with a Cox regression model to identify the factors independently associated with the appearance of non-pathological fractures.Results: Data from 97 patients were collected, 45 received FOLFIRINOX and 52 patients received gemcitabine-abraxane. 64% patients had metastasic disease. The median age of patients was 61 (range 33-78). 46 patients were women, 51 patients were men. 83.7% had an ECOG of 0 or 1. The median of number of cycles received was 8.4 cycles for FOLFIRINOX and 9.6 cycles for gemcitabine-abraxane. Considering age, sex, chemotherapy (QT) scheme, variables associated with fractures, and number of cycles received, the QT regimen used was the only statistically significant factor. There were more non-pathological bone events in the FOLFIRINOX group (OR 40.62; 95% CI, P < 0.041) than in the gem-abraxane group.Conclusions: Our study confirmed that there is a greater risk of bone events in the group receiving FOLFIRINOX, highlighting the importance of careful and detailed evaluation to support the decision to initiate QT. This study was limited by its retrospective design. Real-life evaluations are essential to confirm and sustain indications for treatment and support current clinical practice. More prolonged followup and an increased study population will be important for clearer results.